Bipolar disorders
Bipolar Disorders Overview
Definitions
Bipolar I Disorder:
Characterized by at least one manic episode.
Prevalence: 1% in the U.S.
Bipolar II Disorder:
Involves at least one hypomanic episode and one depressive episode.
No history of manic episodes.
Cyclothymic Disorder:
Duration: Minimum of 2 years.
Symptoms include mild manic-like and depressive-like symptoms (not meeting full criteria).
Prevalence: ~4%.
Manic Episode
Criteria (Duration: 1 week or less if hospitalized)
Mood:
Distinctly elevated, expansive, or irritable.
Activity:
Persistently increased goal-directed activity.
Additional Symptoms (At least 3 required)
Rapid speech.
Flight of ideas/racing thoughts.
Decreased need for sleep.
Increased self-esteem (grandiosity).
Distractibility.
Excessive involvement in activities likely to lead to painful consequences (e.g., spending sprees, sexual indiscretions, unrealistic business ventures).
Exclusions
Symptoms must not be attributable to substance use or a medical condition.
Hypomanic Episode
Symptoms:
Milder than manic episodes.
No significant impairment due to hypomanic episode.
Impairment:
Depressive episodes may cause substantial impairment.
The Manic-Depressive Spectrum
Categories:
Bipolar I
Bipolar II
Cyclothymic
Normal mood variation
Etiology of Bipolar Disorder
Heritability
Estimates as high as 93% for Bipolar I Disorder and also significantly high for Bipolar II.
Neurotransmitter Factors
Potential issues include:
Overly sensitive dopamine receptors.
Dysregulation of norepinephrine.
Psychosocial Contributions
Factors influencing manic episodes:
Shifts in sleep cycle.
Increased activity and accomplishments.
Increased reward sensitivity.
Treatments for Bipolar Disorder
Medications
Common Medications:
Lithium.
Mood stabilizers (e.g., Depakote).
Antipsychotics (e.g., Zyprexa).
Psychological Treatments
Approaches include:
Psychoeducation for the patient and family.
Symptom identification.
Activity regulation through Interpersonal and Social Rhythm Therapy.
Promotion of medication adherence.